- Sepsis claims nearly 11 million lives annually, accounting for 20% of global deaths.
- Santersus' NucleoCapture device targets NETs to improve sepsis outcomes.
- Terumo Ventures invests in Santersus' Series A to accelerate technology development.
- NUC-CAP clinical study to be conducted in the U.S., UK, and EU.
Sepsis Impact
Sepsis is a leading cause of death globally, responsible for nearly 11 million fatalities each year, which is 20% of all global deaths. It surpasses cancer in mortality rates, with over 48 million people affected annually.
Collaborative Effort
Terumo Blood and Cell Technologies and Santersus AG have partnered to advance a novel therapeutic apheresis technology aimed at improving outcomes for sepsis patients. This collaboration combines Santersus' NucleoCapture blood purification technology with Terumo BCT's Spectra Optia™ Apheresis System.
Technological Innovation
The NucleoCapture device is designed to selectively remove neutrophil extracellular traps (NETs) from blood plasma, which are linked to severe sepsis progression. The Spectra Optia system facilitates this process by separating plasma from blood, treating it, and returning it to the patient in one session.
Clinical Development
Santersus will lead the pivotal NUC-CAP clinical study in the U.S., UK, and EU, with Terumo BCT supporting the clinical development. Terumo Ventures is investing in Santersus' Series A financing round to accelerate the development of this technology.
